- Enrollment continued in the ongoing Phase 1b trial of VY-AADC01 for advanced Parkinson’s disease. In October 2015, reported encouraging interim clinical results and Voyager continues to expect to report top-line human proof-of-concept data in the second half of 2016.
Catalyst
Slingshot members are tracking this event:
Phase 1b data of VY-AADC01 for Parkinson's Disease due 2H 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VYGR | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 22, 2016
Occurred Source:
http://ir.voyagertherapeutics.com/phoenix.zhtml?c=254026&p=irol-newsArticle&ID=2179226
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1b Data, Vy-aadc01, Parkinson's Disease, 2h 2016
